- The recently-discovered co-receptors for HIV, CC-CKR-5 and fusin, have led to speculation that these receptors and the chemokines which bind to them may form the basis for a new generation of anti-HIV drugs. It now appears that fusin acts largely as the co-factor for HIV entry into lymphocytes, while CC-CKR-5 is the principal cofactor for entry into macrophages. Administration of certain beta chemokines, such as RANTES, MIP-1 alpha and MIP-1 beta, has been shown to inhibit HIV-1 replication in vitro.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze